URGN compared with CADL: revenue, margins and what each company keeps, and the suppliers and customers both name

URGNUroGen Pharma Ltd.

Mkt capRevenueRevenue

CADLCandel Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

URGNUroGen Pharma Ltd.

CADLCandel Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

URGNUroGen Pharma Ltd.

32.70▼−4.83%· post 34.42

Mkt cap$1.7BRevenue$72MQ2 FY26Revenue$110MFY25

CADLCandel Therapeutics, Inc.

8.83▲+8.68%· post 8.95

ClosedNov 3 '26

Mkt cap$621.3MRevenue—Revenue—

Compare

ClosedNov 3 '26

URGNUroGen Pharma Ltd.

CADLCandel Therapeutics, Inc.

32.70▼−4.83%post 34.42

Price

8.83▲+8.68%post 8.95

$1.7B

Mkt cap

$621.3M

Q2 FY26$72M

Revenue

—

FY25$110M

Revenue

—

URGN32.70▼−4.83%vsCADL8.83▲+8.68%ClosedNov 3 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

URGN: latest quarter is a loss; flow not drawable. CADL: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only URGN 6

AGENAgenussupplier

TEVATeva Pharmaceuticals Industriessupplier

—Cenexi-Laboratories Thissenunlistedsupplier

—IconOVir Biounlistedsupplier

2 more · URGN chain ›

Shared 0

No disclosed counterparties: CADL.

Only CADL 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

URGN, solidCADL, dashed